

Special Issue

New Insights in Tumor-Infiltrating Lymphocytes

Message from the Guest Editors

We are living in an era where single-cell and multi-omics technologies are holding the potential to revolutionize the way to characterize the immune cells within the microenvironment and study their diversity, clonal distribution, pathways, and crosstalk. Tumor-infiltrating lymphocytes (TILs) are deserving of particular attention because they can be used as direct treatment mediators exerting an effective antitumor activity with low side effects per se. However, within the microenvironment, TILs engaged in tumor cell elimination become dysfunctional. In light of this very important clinical objective, we need your innovative and original contribution to capture new insights in:

- Prognostic significance of TILs in solid cancers;
- Dysfunction in the relationship with the interaction with the microenvironment;
- Potential therapeutic reprogrammability;
- Identification of accessible markers to predict the functionality of TILs and/or their reprogramming.

Guest Editors

Dr. Serena Pellegatta

Unit of Immunotherapy of Brain Tumors, Department of Molecular Neuro-Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133 Milan, Italy

Dr. Natalia Di Ianni

Unit of Immunotherapy of Brain Tumors, Department of Molecular Neuro-Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133 Milan, Italy

Deadline for manuscript submissions

closed (31 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/99070

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)